How is sleep-disordered breathing linked with biomarkers of Alzheimer’s disease?

Mohammad Akradi; Tara Farzane-Daghigh; Amir Ebneabbasi; Hanwen Bi; Alexander Drzezga; Bryce A. Mander; Simon B. Eickhoff; Masoud Tahmasian; the Alzheimer’s Disease Neuroimaging Initiative

doi:10.1101/2023.08.16.23294054

Abstract

Sleep-disordered breathing (SDB) is prevalent in Alzheimer’s disease (AD). We assessed whether and how SDB affects neuroimaging biomarkers of AD, including amyloid-beta plaque burden (Aβ), regional uptake of fluorodeoxyglucose using positron emission tomography (rFDG-PET), grey matter volume (GMV), as well as cognitive scores and cerebrospinal fluid (CSF) biomarkers.

Methods We selected 757 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database based on cognitive status (AD, mild cognitive impairment (MCI), cognitively unimpaired (CU)), and SDB condition (with/without SDB). To ensure the reliability of our findings and considering imbalanced sample size across groups, we used a stratified subsampling approach generating 10,000 subsamples (n=10/group). We then selected 512 subsamples with matched covariates. The effect size of the cognitive status-SDB interaction was computed for each biomarker and cognitive score. For reference, we computed 1000 null models by shuffling group labels randomly. The average value of effect sizes for each biomarker in each region was estimated through bootstrapping with 10,000 iterations for both the main and null models and compared with the null model’s distribution. Linear regression models were next implemented to identify associations between the effect size on Aβ, rFDG, and GMV with the effect size on cognitive scores and CSF biomarkers across all subsamples.

Results The cognitive status-SDB interaction had a medium-sized effect on Aβ, rFDG and GMV biomarkers in several brain areas. The effect sizes of the mentioned interactions on Aβ plaque burden in the right precuneus, left middle temporal gyrus, and left occipital fusiform gyrus were associated with the effect sizes of the interactions on cognitive scores. Further, the interaction effect sizes on CSF Aβ42 were related to the interaction effect sizes on Aβ in the right precuneus and posterior cingulate cortex, as well as rFDG in the left precuneus cortex and GMV in bilateral angular gyrus and right occipital fusiform gyrus. Effect sizes on CSF p-tau were also correlated with the effect sizes on Aβ in the left lateral occipital cortex and GMV in the left middle temporal gyrus.

Conclusion We observed that SDB interacts with neuroimaging and CSF biomarkers of AD. Specifically, SDB has a robust association with markers of Aβ pathology in PET and CSF relative to rFDG and GMV in the AD group. The cognitive status-SDB interaction on Aβ is associated with cognitive decline. This study further supports the hypothesis that SDB may precipitate AD pathology.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We used the public datasets from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes